Despite advances in HIV prevention and treatment, disparities persist in access to sexual health services, especially for women. Three posters presented at IDWeek 2024 highlighted the important role of educational efforts in raising women’s awareness of pre-exposure prophylaxis (PrEP) and facilitating access to HIV testing services.
Read more: Women’s Health Resource Center
Learn more about IDWeek here.
Don’t be left behind: Sign up today for our free Drug Topics newsletter to get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.
References 1. Sheth AN, Vincent SY, Simone L et al. Impact of customized education on sexual health and participation in HIV prevention services among U.S. women. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-523.2. Poteat T, Sarkar S, Ragone L, et al. PrEP awareness and engagement opportunities: A survey of U.S. cisgender women seeking medical care. Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-528.3. Short WR, Patel P, Verdier G, et al Pregnancy data with DTG and/or 3TC antiretroviral therapy predict the efficacy and safety of dolutegravir/lamivudine (DTG.3TC) in pregnant women living with HIV-1. , and estimate pharmacokinetics (PK). Presentation location: IDWeek 2024; October 16-19, 2024. Los Angeles, California. Poster P-574.
Source link
